Colitis-Associated Cancer
https://libcat.nshealth.ca/en/permalink/provcat40391
Masato Kusunoki, editor.
(1st ed.)
--Tokyo:
Springer Japan
, c2016.
- Available Online
- View e-Book
- Location
- Online
As the number of patients with colitis-associated cancer (CAC) is on the increase, the purpose of this book is to review the latest topics concerning management of the disease. In recent years, the diagnostic power of endoscopy and molecular pathology has also grown tremendously, as a result of which they now have a far greater influence on the treatment of CAC. At the moment, appropriate monitoring programs for ulcerative colitis and Crohn's disease remain uncertain. At the same time, the late…
- Available Online
- View e-Book
- Other Authors
- Kusunoki, Masato
- Responsibility
- Masato Kusunoki, editor
- Edition
- 1st ed.
- Place of Publication
- Tokyo
- Publisher
- Springer Japan
- Date of Publication
- c2016
- Physical Description
- 1 online resource (viii, 150 p. : 21 illus., 15 illus. in color)
- ISBN
- 9784431555223
- 9784431555216 (print ed.)
- Abstract
- As the number of patients with colitis-associated cancer (CAC) is on the increase, the purpose of this book is to review the latest topics concerning management of the disease. In recent years, the diagnostic power of endoscopy and molecular pathology has also grown tremendously, as a result of which they now have a far greater influence on the treatment of CAC. At the moment, appropriate monitoring programs for ulcerative colitis and Crohn's disease remain uncertain. At the same time, the latest findings on DNA methylation and microRNAs hold the promise of making revolutionary changes in these areas. Moreover, recent drug advances in the treatment of inflammatory bowel diseases have changed surgical indications. On the other hand, the indication of mucosectomy on colorectal cancer in ulcerative colitis and prophylactic abdominoperineal resection for Crohn's disease remain controversial. This book provides the latest information on the remaining issues of CAC from the point of view of expert surgeons.
- Contents
- 1. Colitis-Associated Cancer: Overview -- Part I. Clinical Features -- 2. Incidence and Risk Factors -- 3. Prevention and Prognosis -- Part II. Diagnosis -- 4. Cancer Surveillance of Patients with Long-Standing Inflammatory Bowel Disease -- 5. Molecular Alterations in Inflammatory Colonic Carcinogenesis and Markers for Detecting Colitis-Associated Cancer -- Part III. Surgical Treatment -- 6. Surgical Treatment for Ulcerative Colitis-Associated Cancer or Dysplasia -- 7. Surgical Treatment for Colorectal Cancer in Crohn's Disease.
- Format
- e-Book
- Location
- Online
Golimumab (Simponi®) for inflammatory bowel disease (IBD)
https://libcat.nshealth.ca/en/permalink/chpams35651
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program.
Halifax, NS:
Nova Scotia Health Authority
, 2022.
- Pamphlet Number
- 1641
- Available Online
- View Pamphlet
Your health care provider feels that treatment with golimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what golimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2022
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (12 p.) : digital, PDF file
- Subjects (MeSH)
- Golimumab
- Inflammatory Bowel Diseases - drug therapy
- Subjects (LCSH)
- Inflammatory bowel diseases
- Specialty
- Medications
- Abstract
- Your health care provider feels that treatment with golimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what golimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
- Notes
- Previous title: Golimumab (Simponi) therapy
- Responsibility
- Prepared by: Nova Scotia Collaborative IBD Program
- Pamphlet Number
- 1641
